V
Velarion™Intelligence
Sign InFree TrialBook a Walkthrough
MedTech & Diagnostics

ResMed Executive Compensation (FY26)

RMD · Executive and director compensation, fiscal 2022 to 2026
Chief executive, fiscal 2026
◇
Michael Farrell
Latest say-on-pay support
=
November 19, 2025
Chief executive pay ratio
◇
To the median employee
Velarion Member: every covered company in MedTech & Diagnostics, with dashboards, peer screens and board-ready briefs. Three seats, one year.
Email me this page as a cited PDF — sent in 2 minutes
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.

The paid brief on ResMed

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $499 for the board report; $2,400 for both.
Get the executive briefGet the board briefNo account needed.
Data as of October 22, 2026Latest filing (DEF 14A): October 1, 2026
12 filings cited on this page
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
ResMed brief$1,500Get the executive brief
Velarion Member, one year
395 figures on this page: 387 cited to the filing that reported them, 8 calculated from figures it prints. See the citations

More on ResMed

Five data products on this company. Each one is requested through the developer setup page.
What changed from fiscal 2025 to fiscal 2026
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Michael Farrell: $14,674,543 → $16,201,649 (10.4% higher)
Say-on-pay support: 84.3% → 89.9% (5.6 points higher)
CEO pay ratio: 187:1 → 199:1 (6.4% higher)

Frequently asked questions

Answers drawn from the data on this page.
Who is ResMed's chief executive and what were they paid?
Total compensation for Michael Farrell, Chief executive officer, came to $16,201,649 in fiscal 2026. Compared with the $14,674,543 reported for fiscal 2025, Farrell's total was 10.4% higher.
What was ResMed's say-on-pay result?
The say-on-pay proposal drew 89.9% of votes cast for or against in favor at the meeting held November 19, 2025 for fiscal 2025.
Which companies are in ResMed's peer group?
The disclosed peer group includes Agilent Technologies, Inc., Align Technology, Inc., Baxter International, Inc., Bio-Rad Laboratories, Inc. and Charles River Laboratories International, Inc., among others. The Australian Peer Group includes Amcor, James Hardie Industries PLC, REA Group and Xero.
What is ResMed's chief executive pay ratio?
For fiscal 2026, the company reported a chief executive pay ratio of 199:1, against median employee compensation of $81,585.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Michael Farrell
Chief executive officer
◇—◇—◇—◇◇
Rob Douglas
President and chief operating officer
◇—◇◇◇—◇◇
Jim Hollingshead
President – sleep and respiratory care business
◇—◇———◇◇
Brett Sandercock
Chief financial officer
◇—◇—◇—◇◇
Bobby Ghoshal
President - SaaS business
◇—◇—◇—◇◇
David Pendarvis
Chief Administrative Officer and Global General Counsel
◇—◇◇◇—◇◇
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Michael Farrell
Chief executive officer
◇—◇◇◇—◇◇
Rob Douglas
President and chief operating officer
◇—◇◇◇—◇◇
Lucile Blaise
President - Sleep and
◇—◇◇◇—◇◇
Bobby Ghoshal
President - SaaS business
◇—◇◇◇—◇◇
Brett Sandercock
Chief financial officer
◇—◇—◇—◇◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Michael Farrell
Chief executive officer
◇—◇◇◇—◇◇
Justin Leong
Chief product officer
◇—◇—◇—◇◇
Brett Sandercock
Former chief financial officer and special advisor to CEO
◇—◇—◇—◇◇
Michael Rider
Global general counsel and secretary
◇—◇—◇—◇◇
Fiscal 2025
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Michael Farrell
Chairman of the Board and Chief Executive Officer
◇—◇◇◇—◇◇
Justin Leong
Chief Product Officer
◇—◇—◇—◇◇
Bobby Ghoshal
Chief Commercial Officer, Residential Care Software
◇—◇—◇—◇◇
Brett Sandercock
Chief Financial Officer
◇—◇—◇—◇◇
Michael Rider
Global General Counsel and Secretary
◇—◇—◇—◇◇
Fiscal 2026
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Michael Farrell
Chief executive officer
◇—◇◇◇—◇◇
Justin Leong
Chief product officer
◇—◇—◇—◇◇
Brett Sandercock
Former chief financial officer and special advisor to CEO
Departed during or after this year
◇—◇—◇—◇◇
Aaron Bloomer
Chief financial officer
◇—◇—◇—◇◇
Michael Rider
Global general counsel and secretary
◇—◇—◇—◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2026
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
Aaron BloomerPSU◇◇◇—◇—◇
Aaron BloomerPSU◇◇◇—◇—◇
Aaron BloomerPSU◇◇◇—◇—◇
Brett SandercockPSU◇◇◇—◇—◇
Brett SandercockPSU◇◇◇—◇—◇
Brett SandercockPSU◇◇◇—◇—◇
Justin LeongPSU◇◇◇—◇—◇
Justin LeongPSU◇◇◇—◇—◇
Justin LeongPSU◇◇◇—◇—◇
Michael FarrellPSU◇◇◇—◇—◇
Michael FarrellPSU◇◇◇—◇—◇
Michael FarrellPSU◇◇◇—◇—◇
Michael FarrellOPTION◇——◇—◇◇
Michael RiderPSU◇◇◇—◇—◇
Michael RiderPSU◇◇◇—◇—◇
Michael RiderPSU◇◇◇—◇—◇
Fiscal 2022, 2023, 2025 are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2026 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
Michael FarrellPSU◇◇——
RSU◇◇——
RSU◇◇——
PSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇—
Option◇—◇—
Option◇—◇—
Option◇—◇—
Option◇—◇—
Brett SandercockRSU◇◇——
RSU◇◇——
PSU◇◇——
PSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
Justin LeongRSU◇◇——
PSU◇◇——
RSU◇◇——
PSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇—
RSU◇◇——
RSU◇◇——
Option◇—◇—
Option◇—◇—
Aaron BloomerRSU◇◇——
RSU◇◇——
RSU◇◇——
Michael RiderPSU◇◇——
RSU◇◇——
PSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Severance and change in control

The terms as written in the agreements.
Justin Leong
Chief product officer · Terms as described in the company’s compensation discussion · citing a 2025 filing
Severance multiple◇
Severance cash amount◇
Change-in-control multiple◇
Benefits continuation on change in control◇
Benefits continuation◇
Non-compete period◇
Non-solicit period◇
Michael Rider
Global general counsel and secretary · Terms as described in the company’s compensation discussion · citing a 2025 filing
Severance multiple◇
Change-in-control multiple◇
Benefits continuation on change in control◇
Benefits continuation◇
Non-compete period◇
Non-solicit period◇

Director compensation

What each non-employee director was paid.
Fiscal 2026
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Peter Farrell
◇◇◇——◇◇
Ronald Taylor
Lead independent director
◇◇————◇
Nicole Mowad-Nassar
◇◇◇———◇
Christopher DelOrefice
◇◇————◇
Karen Drexler
◇◇————◇
Carol Burt
◇◇————◇
Harjit Gill
◇◇————◇
Desney Tan
◇◇————◇
John Hernandez
◇◇————◇
Jan De Witte
◇◇————◇
Richard Sulpizio
◇—————◇
Michael Farrell served on the board in fiscal 2026 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Board equity retainer◇
Total board retainer◇
Lead independent director premium◇
Audit committee chair◇
Compensation committee chair◇
Nominating and governance chair◇
Equity is delivered as Rsus/Options.

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2026
  • Agilent Technologies, Inc. A
  • Align Technology, Inc. ALGN
  • Baxter International, Inc. BAX
  • Bio-Rad Laboratories, Inc. BIO
  • Charles River Laboratories International, Inc. CRL
  • Dexcom, Inc. DXCM
  • Edwards Lifesciences Corp. EW
  • Hologic Inc. HOLX
  • IDEXX Laboratories, Inc. IDXX
  • Illumina, Inc. ILMN
  • Intuitive Surgical, Inc. ISRG
  • Mettler-Toledo International Inc. MTD
  • Teleflex Incorporated TFX
  • The Cooper Companies Inc. COO
  • Waters Corporation WAT
Australian Peer Group
  • Amcor AMCR
  • James Hardie Industries PLC JHX
  • REA Group symbol not shown
  • Xero XRX

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2025November 19, 2025=◇◇◇
2024November 20, 2024=◇◇◇
2023November 16, 2023=◇◇◇
2022November 16, 2022=◇◇◇
2021November 18, 2021=◇◇◇
2020November 19, 2020=◇◇◇
2019November 21, 2019=◇◇◇
2018November 14, 2018=◇◇◇

Chief executive pay ratio

As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇

Velarion Pro: every company page, peer tools and exports, one seat

One seat, one person. It opens the whole platform: the peer tools, the written analysis and the exports, on every company we cover. Join the list and you will hear from us when it opens.
Your address is used for this and nothing else, and you can unsubscribe in one click. See the privacy policy.

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”
- Michael Farrell (Chief executive officer), FY2026 total compensation $16,201,649 (base salary $1,272,895) [exec_comp, SEC accession 0000943819-26-000080, filed 2026-10-01]

Answered within 24 hours, every figure cited to its SEC filing. If our database cannot answer your question, you are refunded automatically.

Tell me when ResMed files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact ResMed disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where ResMed sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $499
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for Peer Group Review
Whether ResMed's disclosed peer group is defensible, who names ResMed back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
395 figures on this page: 387 cited to the filing that reported them, 8 calculated from figures it prints.
387 cited to the filing
8 calculated from the filing

Documents cited

  1. 0000943819-26-000080
    Director Compensation · Executive Compensation Tables
  2. 0001193125-25-289878
    Proposal 5 Approval of the Amendment and Restatement of the ResMed Inc.
  3. 0000943819-25-000079
    Compensation Discussion and Analysis · Summary Compensation Table
  4. 0001193125-24-263501
    Item 5.07 Submission of Matters to a Vote of Security Holders
  5. 0001193125-23-280656
    Item 5.07 Submission of Matters to a Vote of Security Holders
  6. 0000943819-23-000019
    Summary compensation table
  7. 0001193125-22-287662
    Item 5.07 Submission of Matters to a Vote of Security Holders
  8. 0000943819-22-000014
    Summary compensation table
  9. 0001193125-21-334941
    Item 5.07 Submission of Matters to a Vote of Security Holders
  10. 0001193125-20-299382
    Item 5.07 Submission of Matters to a Vote of Security Holders
  11. 0001193125-19-298542
    Item 5.07 Submission of Matters to a Vote of Security Holders
  12. 0001193125-18-328956
    Item 5.07 Submission of Matters to a Vote of Security Holders
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “ResMed executive compensation, FY2022–FY2026.” https://intel.velarion.ai/comp/RMD (accessed 2026).
Short form: data: Velarion

The paid brief for ResMed

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $499 for the board report; $2,400 for both.
Get the executive briefGet the board briefNo account needed.
12 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about ResMed and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

MedTech & Diagnostics rankings

Chief executive pay — MedTech & DiagnosticsCEO pay ratio — MedTech & DiagnosticsSay-on-pay support — MedTech & Diagnostics

Peers ResMed discloses

The companies named in RMD's own disclosed peer group.

Agilent Technologies, Inc.Align Technology, Inc.Baxter International, Inc.Bio-Rad Laboratories, Inc.Charles River Laboratories International, Inc.Dexcom, Inc.Edwards Lifesciences Corp.Hologic Inc.IDEXX Laboratories, Inc.Illumina, Inc.Intuitive Surgical, Inc.Mettler-Toledo International Inc.Teleflex IncorporatedThe Cooper Companies Inc.Waters CorporationAmcorJames Hardie Industries PLCXero

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies

Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.

Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  All companies · The Pay Desk · Methodology · Terms · Privacy